The role of combination medical therapy in acromegaly: Hope for the nonresponsive patient

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


PURPOSE OF REVIEW: This review focuses on combination drug treatment for acromegaly patients, including novel concepts and experimental therapies, with an emphasis on the author's personal experience. RECENT FINDINGS: A review of published clinical studies demonstrates that combination therapy; somatostatin receptor ligands and dopamine agonists, somatostatin receptor ligands and pegvisomant, or cabergoline and pegvisomant could provide significant additive biochemical control of acromegaly in patients inadequately controlled with conventional somatostatin receptor ligand therapy. SUMMARY: Advances in combination medical therapy have opened up new perspectives for acromegaly patients who are poorly, or nonresponsive to, presently available single drug therapies.

Original languageEnglish (US)
Pages (from-to)321-329
Number of pages9
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number4
StatePublished - Aug 2013


  • acromegaly
  • combination therapy
  • dopamine agonists
  • growth hormone receptor antagonist
  • somatostatin receptor ligands

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics


Dive into the research topics of 'The role of combination medical therapy in acromegaly: Hope for the nonresponsive patient'. Together they form a unique fingerprint.

Cite this